PTEN and non-small cell lung carcinoma: Missense mutations and amplifications, in ~20% of advanced SqCC, frequently associated with loss of PTEN, worse prognosis, buparlisib showed poor disease responses with only 20% PFS at 12 weeks among NSCLC patients with PIK3CA activating mutations